Finerenone: a breakthrough mineralocorticoid receptor antagonist for heart failure, diabetes and chronic kidney disease

Akshyaya Pradhan, Umesh Chandra Tripathi · 2024

Read Finerenone: a breakthrough mineralocorticoid receptor antagonist for heart failure, diabetes and chronic kidney disease by Akshyaya Pradhan, Umesh Chandra Tripathi (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11649598.txt.

Description

Akshyaya Pradhan and Umesh Tripathi review a new drug called finerenone. Their review from twenty twenty-four deals with heart failure, diabetes, and kidney disease. The drug blocks a hormone that holds salt and water.

That hormone also drives scar growth in the heart over time. Older blockers work well but can bring harsh side effects. Finerenone is pitched as strong as the oldest drug with fewer harms. Traits of the drug are set next to the older options. Best uses for each patient type are also weighed. Future paths for the drug are sketched.

Catalog record

CREATORAkshyaya Pradhan, Umesh Chandra Tripathi
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE35 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11649598

Browse the full library · About the Tower of Babel